Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | MAT2A | P31153 | 6/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27051340 | 1.00 | TNF (0.46) | TNFNR4A2MAT2AROCK1KDM4E | |
| SCHEMBL11852556 | 0.82 | NR4A2 (0.43) | TNFNR4A2ROCK1KDM4EALDH1A1 | |
| SCHEMBL509135 | 0.80 | EGFR (0.42) | TNF | |
| SCHEMBL8313102 | 0.80 | CCR1 (0.42) | ALDH1A1METAP2METAP1 | |
| SCHEMBL24151604 | 0.79 | PLAU (0.47) | TNFALDH1A1LMNA | |
| SCHEMBL16455340 | 0.79 | CTDSP1 (0.38) | TNFKDM4EALDH1A1LMNA | |
| SCHEMBL17964000 | 0.76 | TNF (0.50) | TNF | |
| SCHEMBL2757280 | 0.76 | CYP2A6 (0.53) | NR4A2ROCK1ALDH1A1SOS2 | |
| SCHEMBL31352410 | 0.76 | TNF (0.42) | TNFKDM4ELMNA | |
| SCHEMBL1317870 | 0.75 | LMNA (0.50) | NR4A2ROCK1ALDH1A1LMNAMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4558479-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119546572-A | Novel naphthyl and isoquinoline sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024017858-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | CBR3, HAX1, CBR1 | TNF 4790/4885NR4A2 100/4885MAT2A 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.